What is the recommended adult dose of oseltamivir (Tamiflu) for treating influenza and for post‑exposure prophylaxis, and how should the dose be adjusted in renal impairment?

Adult Dose of Oseltamivir

For adults, the standard dose of oseltamivir is 75 mg twice daily for 5 days for treatment of influenza, and 75 mg once daily for at least 10 days for post-exposure prophylaxis. 1, 2

Treatment Dosing

The FDA-approved treatment regimen for adults and adolescents 13 years and older is 75 mg orally twice daily for 5 days 2. This dosing is consistent across multiple guideline sources 3, 1, 4.

Key treatment considerations:

• Therapy should be initiated within 48 hours of symptom onset for maximum benefit
• Can be taken with or without food, though administration with meals may improve gastrointestinal tolerability 2
• Available as 30 mg, 45 mg, and 75 mg capsules, or as oral suspension (6 mg/mL concentration) 1, 2

Prophylaxis Dosing

For post-exposure prophylaxis, the dose is 75 mg once daily 1, 2. The duration varies by indication:

• Post-exposure prophylaxis (household contact): 75 mg once daily for at least 10 days, starting within 2 days of exposure 2
• Community outbreak prophylaxis: 75 mg once daily for up to 6 weeks in immunocompetent patients, or up to 12 weeks in immunocompromised patients 2

Renal Dose Adjustments

Critical dosing modifications are required for renal impairment to prevent drug accumulation, as oseltamivir is renally cleared 3, 2:

For creatinine clearance 10-30 mL/min:

• Treatment: 75 mg once daily for 5 days (reduced from twice daily) 3, 2
• Prophylaxis: Either 75 mg every other day OR 30 mg once daily for 10 days after exposure 3, 2

For end-stage renal disease (ESRD):

• Hemodialysis patients: 30 mg after alternate dialysis sessions (three times weekly) 5
• CAPD patients: 30 mg once weekly after dialysate exchange 5

Important caveat: Recent evidence suggests that current dose reductions for mild-to-moderate renal impairment may delay achievement of therapeutic concentrations in the critical early infection period 6. The first dose should be 75 mg even in renal impairment, with subsequent doses reduced proportionally 6. However, this conflicts with FDA labeling and should be considered on a case-by-case basis with therapeutic drug monitoring when available.

Special Populations

No dose adjustment is required for:

• Geriatric patients 2
• Patients with mild or moderate hepatic impairment (Child-Pugh score ≤9) 2

Patients with large body mass: Standard 75 mg dosing may be inadequate for patients with significantly elevated body mass, potentially requiring proportionately larger doses 6. This is not reflected in current FDA labeling but represents emerging evidence.

Common Pitfalls

1. Delaying treatment beyond 48 hours: Efficacy is significantly reduced when treatment is not initiated promptly 2
2. Failing to adjust for renal impairment: This can lead to drug accumulation and increased adverse effects 3, 2
3. Using oseltamivir as a substitute for vaccination: Antivirals are adjunctive therapy, not a replacement for annual influenza vaccination 1, 4
4. Inadequate prophylaxis duration: Post-exposure prophylaxis requires at least 10 days, not the 5-day treatment course 2